Oral bisphosphonates and intravenous receptor activator of nuclear factor kappa-B ligand antibodies are the main clinical therapeutic drugs for osteoporosis (Tella and Gallagher, 2014), which both repress osteoclast activity. Here, TNFSF11 is linked to osteoporosis.